Retirement Systems of Alabama reduced its position in shares of Haemonetics Co. (NYSE:HAE) by 1.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 66,802 shares of the medical instruments supplier’s stock after selling 801 shares during the period. Retirement Systems of Alabama’s holdings in Haemonetics were worth $7,654,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in HAE. Renaissance Technologies LLC raised its position in Haemonetics by 49.3% during the second quarter. Renaissance Technologies LLC now owns 1,969,700 shares of the medical instruments supplier’s stock valued at $176,643,000 after purchasing an additional 650,200 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in Haemonetics during the second quarter valued at approximately $18,272,000. Acadian Asset Management LLC raised its position in Haemonetics by 28.3% during the second quarter. Acadian Asset Management LLC now owns 888,097 shares of the medical instruments supplier’s stock valued at $79,646,000 after purchasing an additional 196,154 shares in the last quarter. American Century Companies Inc. raised its position in Haemonetics by 154.3% during the second quarter. American Century Companies Inc. now owns 303,808 shares of the medical instruments supplier’s stock valued at $27,246,000 after purchasing an additional 184,324 shares in the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd raised its position in Haemonetics by 54.7% during the third quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 483,484 shares of the medical instruments supplier’s stock valued at $55,397,000 after purchasing an additional 171,049 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.
HAE has been the subject of several research analyst reports. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Barrington Research restated a “buy” rating and set a $127.00 price objective on shares of Haemonetics in a research report on Friday, October 5th. Morgan Stanley boosted their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 7th. Finally, Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective for the company in a research report on Friday, October 12th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $102.67.
Shares of NYSE:HAE opened at $105.34 on Friday. The firm has a market cap of $5.40 billion, a PE ratio of 56.33, a P/E/G ratio of 3.39 and a beta of 1.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.84 and a quick ratio of 1.94. Haemonetics Co. has a 52-week low of $46.25 and a 52-week high of $117.56.
Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.17. The company had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. On average, sell-side analysts anticipate that Haemonetics Co. will post 2.28 EPS for the current year.
In other news, SVP Jacqueline Scanlan sold 4,890 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $112.19, for a total transaction of $548,609.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pedro P. Granadillo sold 30,824 shares of the company’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $111.83, for a total transaction of $3,447,047.92. The disclosure for this sale can be found here. Insiders have sold 37,275 shares of company stock valued at $4,069,830 over the last quarter. Company insiders own 1.04% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.